Bush Jennifer
Known title: COO, CLO, Compliance OfficerCIK: 0001621152
Associated companies
Transaction History
| ARTV | ▼ Sell | Open Market | 8,370 | $57K | 10/5/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 45,000 | $0 | 9/9/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 8,391 | $94K | 9/3/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 8,790 | $79K | 5/19/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 117,300 | $0 | 2/15/2026 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 3,515 | $14K | 2/15/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 84,877 | $0 | 12/12/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 3,055 | $10K | 11/15/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 6,409 | $18K | 8/15/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 1,937 | $4K | 5/15/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 86,650 | $0 | 2/26/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 50,000 | $0 | 9/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium
Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.